newsfilter
← Latest News
Business Wire·

Karuna Therapeutics Reports First Quarter 2023 Financial Results and Provides General Business Updates

Announced positive topline data from the Phase 3 EMERGENT-3 trial of KarXT in schizophrenia in the first quarter of 2023 On track to submit New Drug Application (NDA) for KarXT in schizophrenia with the U.S. FDA in